Search peptides, terms, sources/
Hormonal signalling

Abaloparatide

Synthetic 34-amino-acid peptide modelled on PTHrP, studied for osteoporosis. UK prescription-only medicine; the main trial compared it with placebo.

UK status and evidence last reviewed .

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

UK status
Licensed UK medicineChecked
Best study type
Human trials4 human trials · 1 human observational

What is Abaloparatide?

Abaloparatide is a synthetic 34-amino-acid peptide, modelled on parathyroid hormone-related protein (PTHrP), studied as a bone-building treatment for osteoporosis. In the UK it is a licensed prescription-only medicine for postmenopausal women at increased risk of fracture, and in the 2,463-woman ACTIVE trial new vertebral fractures occurred less often than with placebo.

It works by activating the parathyroid hormone type 1 (PTH1) receptor.

Class
Parathyroid hormone receptor agonist (bone-anabolic)
Origin
Analogue / modified
Research areas
Bone Health Research
UK status
Licensed UK medicine
Best study type
Human trials
Evidence last reviewed

How does Abaloparatide work?

According to the UK product information, abaloparatide activates the PTH1 receptor, which stimulates new bone formation by increasing osteoblast activity, with only a transient and limited rise in bone breakdown. It is in the same bone-building group as teriparatide but is modelled on a related protein, so results for one should not be assumed for the other.

The mechanism in more detail

Abaloparatide is a 34-amino-acid peptide that activates the PTH1 receptor signalling pathway. According to the UK product information, it stimulates new bone formation by increasing osteoblast activity, with only transient and limited increases in bone resorption, and it increases bone density.

It belongs to the same bone-building (anabolic) group as teriparatide, which is a fragment of parathyroid hormone itself, whereas abaloparatide is modelled on the related protein PTHrP. Both are given as injections in the trials cited on this site. Results from one drug should not be assumed to apply to the other without direct evidence.

This mechanism account is taken from the UK product information (the SmPC), a regulator-approved manufacturer document, rather than from a single primary structural-biology study.

Mechanisms and targets

Classification and structure

Names
Abaloparatide; Eladynos (UK brand name); PTHrP analogue
Class
Parathyroid hormone receptor agonist (bone-anabolic)
Origin
Analogue / modified
Structure
34-amino-acid synthetic peptide. Published literature describes it as an analogue of PTHrP(1-34) with about 76% homology to PTHrP; the UK product information describes it as a 34-amino-acid peptide that activates the PTH1 receptor signalling pathway.
Routes used in the research
Subcutaneous injection in the trials cited.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Abaloparatide has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
04011

The ACTIVE trial Strong

In the 18-month ACTIVE trial in 2,463 postmenopausal women with osteoporosis, new vertebral fractures occurred less often with abaloparatide than with placebo, as they did in the open-label teriparatide reference group. The estimated non-vertebral fracture rate was lower with abaloparatide than with placebo, and bone mineral density rose more with abaloparatide (all P under .001). Hypercalcaemia (raised blood calcium) was less frequent with abaloparatide than with teriparatide: 3.4% versus 6.4% (P = .006).

Study type
Human trial
Population
2,463 postmenopausal women with osteoporosis (mean age 69; 28 sites in 10 countries); phase 3, double-blind versus placebo, with an open-label teriparatide reference arm.
Source
1 Miller et al., 2016

Limitation: The teriparatide arm was open-label and was a reference comparator, not a powered head-to-head test.

Limitations in full

The teriparatide arm was open-label and was a reference comparator, not a powered head-to-head test. Fracture percentages sit in the full paper's tables; only the direction and the hypercalcaemia figures are quoted from the abstract read on 2026-11-14.

Followed by alendronate (ACTIVExtend) Limited

In the ACTIVExtend extension, women who had received abaloparatide for 18 months and then alendronate for 24 months had new radiographic vertebral fractures in 0.9% over 43 months, versus 5.6% in women who had received placebo and then alendronate (relative risk reduction 84%, P under .001). Hip fractures were 0 versus 5 in a supplemental analysis.

Study type
Human trial
Population
558 women who had received abaloparatide and 581 who had received placebo in ACTIVE, then all given alendronate.
Source
2 Bone et al., 2018

Limitation: Extension study: everyone received alendronate in the second phase, so the result reflects abaloparatide followed by alendronate, not abaloparatide alone.

Limitations in full

Extension study: everyone received alendronate in the second phase, so the result reflects abaloparatide followed by alendronate, not abaloparatide alone. The hip-fracture figures come from a supplemental analysis with very small numbers.

Women at highest fracture risk Limited

In a post hoc analysis of ACTIVE women at the highest fracture risk, new vertebral fractures were 0.72% with abaloparatide, 0.99% with teriparatide and 4.77% with placebo. Major osteoporotic fractures were 1.6%, 3.0% and 6.8%, and clinical fractures 4.0%, 4.3% and 9.0%.

Study type
Human trial
Population
Subgroup of ACTIVE participants at highest fracture risk.
Source
3 DeSapri et al., 2025

Limitation: Post hoc subgroup analysis, so less reliable than the primary trial result.

Limitations in full

Post hoc subgroup analysis, so less reliable than the primary trial result. The abstract reports no hazard ratios, and the trial was not designed to compare abaloparatide with teriparatide.

Bone-density targets Limited

A post hoc modelling analysis of ACTIVE data estimated that, over 18 months, more than half of women were likely to reach a total-hip T-score above -2.5 with either abaloparatide or teriparatide, even from a baseline as low as -2.7.

Study type
Human observational
Population
2,463 women aged 49 to 86 from the ACTIVE trial.
Source
4 Cosman et al., 2025

Limitation: Modelled bone-density targets, not fracture outcomes, and not a direct comparison of the two drugs.

Pelvic fracture healing: no significant benefit Limited No effect shown

In a phase 2 randomised trial of abaloparatide for pelvic fracture healing, the share of patients whose fractures had healed was lower with abaloparatide (39%) than with placebo (64%), a difference that was not statistically significant (relative risk 0.61, 95% CI 0.33 to 1.12). At the level of individual fractures (81), healing was 47% versus 53% (relative risk 0.88, 95% CI 0.55 to 1.40).

Study type
Human trial
Population
Patients with pelvic fractures in a phase 2 placebo-controlled trial.
Source
5 Nieves et al., 2026

Limitation: Small phase 2 trial, ahead of print.

Limitations in full

Small phase 2 trial, ahead of print. The result was not significant, so no benefit or harm can be concluded. Fracture healing is not a licensed use.

Mechanism of action Not graded

Abaloparatide is a 34-amino-acid peptide that activates the PTH1 receptor signalling pathway. It stimulates new bone formation by increasing osteoblast activity, with a transient, limited increase in bone resorption, and it increases bone density.

Study type
Regulatory-clinical source
Population
Pharmacology summary, not a single clinical population.
Source
6 Theramex Ireland Limited (marketing authorisation holder), 2025

Limitation: Mechanism statement from the manufacturer's product information, not a standalone graded claim.

What safety findings have been reported?

3 safety findings are recorded for Abaloparatide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Raised blood calcium

In the ACTIVE trial, hypercalcaemia occurred in 3.4% of women on abaloparatide and 6.4% of women on teriparatide (risk difference -2.96 percentage points, 95% CI -5.12 to -0.87). The UK product information adds that serum calcium peaks about 4 hours after each injection and returns to baseline by 24 hours.

Source
1 Miller et al., 2016

Heart rate, blood pressure and kidney stones

The UK product information warns of orthostatic hypotension (low blood pressure on standing) and increased heart rate, typically within 4 hours of an injection, and of hypercalciuria (extra calcium in urine) with an unknown effect on existing kidney stones. The most common adverse reactions in ACTIVE were hypercalciuria (15.6%), dizziness (11.1%), back pain (8.6%), nausea (8.5%), headache (8.5%), joint pain (8.4%), high blood pressure (6.8%), injection-site reactions (6.2%) and palpitations (5.6%).

Source
6 Theramex Ireland Limited (marketing authorisation holder), 2025

Osteosarcoma in rats

In a 2-year rat study, abaloparatide increased the overall incidence of osteosarcoma (bone tumours) at about 4 times the human systemic exposure. The UK product information states the relevance to humans is uncertain and that use should be avoided in people at increased risk of osteosarcoma.

Source
6 Theramex Ireland Limited (marketing authorisation holder), 2025

What is Abaloparatide's UK regulatory status?

Marketing authorisation
Licensed in the UK. The electronic Medicines Compendium lists Eladynos solution for injection in pre-filled pen, with Theramex Ireland Limited as the marketing authorisation holder.
Prescription status
Prescription-only medicine (POM).
Medicine class
Licensed medicinal product.
MHRA position
Abaloparatide appears on the MHRA Products database active-substance index (checked 14 November 2026). The eMC product record was last updated on 11 April 2025 and the product information text was revised on 22 January 2024.
Authorised use
Treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Other restrictions
NHS funding decisions are separate from the marketing authorisation.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

References

6 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Miller PD, Hattersley G, Riis BJ, et al., ACTIVE Study Investigators (2016). Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMAHuman clinical trial, RCT · DOI 10.1001/jama.2016.11136 · PMID 27533157 · Original ↗
  2. Bone HG, et al. (2018). ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology & MetabolismHuman clinical trial · DOI 10.1210/jc.2018-00163 · PMID 29800372 · Original ↗
  3. DeSapri KT, et al. (2025). Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture. MenopauseHuman clinical trial, Human observational · DOI 10.1097/gme.0000000000002516 · PMID 39999474 · Original ↗
  4. Cosman F, Mitlak BH, Wang Y, Pearman L, Moreira CA, Lewiecki EM, Cummings SR (2025). Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide. Journal of Bone and Mineral ResearchHuman observational · DOI 10.1093/jbmr/zjaf053 · PMID 40214193 · Original ↗
  5. Nieves JW, et al. (2026). Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial. Osteoporosis InternationalHuman clinical trial, RCT · DOI 10.1007/s00198-026-08176-2 · PMID 42618812 · Original ↗
  6. Theramex Ireland Limited (marketing authorisation holder) (2025). Eladynos solution for injection in pre-filled pen (abaloparatide): Summary of Product Characteristics. electronic Medicines Compendium (eMC) · Original ↗

Questions about Abaloparatide

What is Abaloparatide?

Abaloparatide is a synthetic 34-amino-acid peptide, modelled on parathyroid hormone-related protein (PTHrP), studied as a bone-building treatment for osteoporosis. In the UK it is a licensed prescription-only medicine for postmenopausal women at increased risk of fracture, and in the 2,463-woman ACTIVE trial new vertebral fractures occurred less often than with placebo. Read what it is.

Is Abaloparatide licensed in the UK?

PeptGuru records Abaloparatide's UK status as: Licensed UK medicine. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Abaloparatide show?

PeptGuru records 6 research findings for Abaloparatide: 4 from human trials, 1 from a human observational study and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Abaloparatide?

3 safety findings are recorded, including: raised blood calcium; heart rate, blood pressure and kidney stones; osteosarcoma in rats. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Abaloparatide?

All 6 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Abaloparatide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • Teriparatide

    34-amino-acid fragment of parathyroid hormone, studied for osteoporosis. UK prescription-only medicine; trials looked at spine and hip fractures.

    Hormonal signallingHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • KisspeptinMetastin

    Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Oxytocin

    Natural hormone licensed in the UK for obstetric use; studied separately for social cognition, with mostly negative trial results.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedLicensed for a different use

Compare Abaloparatide with Teriparatide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.